For the quarter ending 2026-03-31, SPTX had $6,867K increase in cash & cash equivalents over the period. -$20,172K in free cash flow.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -25,408 |
| Stock-based compensation expense | 2,569 |
| Depreciation expense | 26 |
| Amortization of operating lease right-of-use assets | 331 |
| Net amortization of premium and discounts on investments | -223 |
| Prepaid expenses and other current assets | -1,571 |
| Other non-current assets | 0 |
| Accounts payable | 2,780 |
| Related party payable | 4 |
| Accrued expenses and other current liabilities | -1,499 |
| Operating lease liability | -323 |
| Net cash used in operating activities | -20,172 |
| Purchase of investments | 47,150 |
| Proceeds from maturities of investments | 75,000 |
| Purchases of property and equipment | 0 |
| Net cash provided (used in) investing activities | 27,850 |
| Payment of deferred offering costs | 783 |
| Net cash used in financing activities | -783 |
| Effect of exchange rates on cash and cash equivalents | -28 |
| Net increase (decrease) in cash and cash equivalents | 6,867 |
| Cash, cash equivalents, and restricted cash, beginning of period | 46,496 |
| Cash, cash equivalents, and restricted cash, end of period | 53,363 |
Seaport Therapeutics, Inc. (SPTX)
Seaport Therapeutics, Inc. (SPTX)